Should Investors Hold Chemed Stock in Their Portfolio Now?

Chemed (market cap $8.46B) shows operational momentum driven by its VITAS hospice arm—VITAS reported 17.3% YoY growth in Q3 2024 with admissions up 6.3% and ADC up 15.5% aided by the Covenant Health acquisition—while Roto-Rooter is maintaining market share through service and digital initiatives. The company ended Q3 with $238.5M cash, no debt, repurchased 100,000 shares for $57.8M (≈$578.21/share) and has ~$161.8M buyback authorization remaining; Zacks consensus 2024 EPS is $23.09 and revenue is $2.42B (estimated +6.87% YoY). Offsetting strengths are inflationary and labor pressures (cost of services +9.3% YoY; SG&A +2.4%) and a highly competitive market; the stock is a Zacks #3 (Hold) and is down 5.7% over the past year versus industry and S&P gains.

Analysis

Market structure: VITAS (hospice) is the primary winner — 17.3% YoY growth, ADC +15.5% and admissions +6.3% indicate demand > supply for licensed clinicians, which supports pricing/leverage in hospice but only modest pricing power in fragmented local hospice markets. Roto-Rooter retains brand advantages but faces compressed volumes from weaker consumer spending; local independent plumbing shops gain share in price-sensitive patches. Strong balance sheet (no debt, $238.5M cash, $161.8M repurchase left) lowers financing risk and supports buybacks/dividends as a shareholder-return lever.

Risk assessment: Tail risks include a Medicare/Medicaid reimbursement cut (>5% effective rate) or a sustained labor-cost shock (wage inflation >7% YoY) that could wipe out ~200–400 bps of operating margin. Immediate risks (days–weeks) are headline-driven; short-term (next 2 quarters) risks are ADC volatility and Roto-Rooter seasonal weakness; long-term (12–36 months) risks are regulatory changes and integration failure of acquisitions like Covenant. Hidden dependency: operational leverage in VITAS ties EPS sensitivity to admission cadence — a small decline in census materially moves EPS.

Trade implications: Tactical long CHE exposure is attractive conditional on validated VITAS momentum; use size limits and option overlays to control downside. Cross-asset: CHE’s no-debt profile should tighten credit spreads modestly; equity options implied vol likely cheap relative to event risk — favor buy-write and calendar structures. Rebalance sector exposure toward higher-growth medtech names (VCYT, PAHC) if macro weakens and consumer services underperform.

Contrarian angles: Market is underweight CHE because of Roto-Rooter noise while ignoring sustained hospice acceleration and management buybacks at ~$578/share — an idiosyncratic mispricing. The consensus underestimates durable ADC improvements; conversely if reimbursement policy shifts, downside is sharp and asymmetric. Historical parallel: services with durable demographic tailwinds have re-rated after two consecutive quarters of normalized admissions; use that signal to add exposure.

Key Decisions for Investors

• Establish a 2–3% long position in CHE if price <= $600, target +12–18% upside over 6–12 months; set a hard stop-loss at -12% from entry and reassess after two consecutive quarterly reports.
• If initiating CHE exposure, implement a cost-managed option overlay: buy 12-month (Jan 2026) ATM LEAP calls sized to 50% of directional exposure and sell quarterly 10–15% OTM calls (covered/ratio) to finance ~30–40% of premium; roll or unwind after 2 earnings if ADC growth <3% YoY.
• For market-neutral exposure, pair long CHE (2%) with a short SPY position sized to neutralize beta (~0.4–0.6x notional) for a 3–9 month trade; close or re-weight after next two quarterly earnings or if Medicare reimbursement guidance changes.
• Increase allocation by another 1–2% if VITAS reports ADC growth >10% YoY for two consecutive quarters or management repurchases additional shares at prices <= $578; reduce to zero if cost of services rises >10% YoY or admissions fall below +1% YoY.